证券代码：301515 证券简称：港通医疗 公告编号：2025-021 四川港通医疗设备集团股份有限公司 关于续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召开第四届董事会第十九次会议、第四届监事会第十九次会议，审议通过 《关于续聘会计师事务所的议案》，本议案尚需提交公司 2024 年年度股东会审议。 本次续聘会计师事务所符合财政部、国务院国资委、证监会印发的《国有企业、 上市公司选聘会计师事务所管理办法》的规定，现将相关事宜公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息 名称：致同会计师事务所（特殊普通合伙）（以下简称"致同所"） 成立日期：1981 年（工商登记：2011 年 12 月 22 日） 组织形式：特殊普通合伙企业 注册地址：北京市朝阳区建国门外大街 22 号赛特广场五层 首席合伙人：李惠琦 致同所 2023 年度业务收入 27.03 亿元，其中审计业务收入 22.05 亿元，证券 业务收入 5.02 亿元。 ...

关于四川港通医疗设备集团股份有限公司 2024 年度募集资金 存放与实际使用情况鉴证报告 四川港通医疗设备集团股份有限公司 2024 年度募集资金 存放与实际使用情况的专项报告 1-4 关于四川港通医疗设备集团股份有限公司 2024 年度募集资金存放与实际使用情况 鉴证报告 致同会计师事务所（特殊普通合伙） 目 录 1 关于四川港通医疗设备集团股份有限公司 2024 年度募集资金存放与实际使用情况 鉴证报告 致 同 会 计 师 事 务 所 （特殊普通合伙） 中国北京 朝阳区建 国门外大街 22 号 赛特广场 5 层 邮编 100004 致同专字（2025）第 510A008161 号 四川港通医疗设备集团股份有限公司全体股东： 我们接受委托，对后附的四川港通医疗设备集团股份有限公司（以下简称港通 医疗公司）《2024 年度募集资金存放与实际使用情况的专项报告》（以下简称 "专项 报告"）执行了合理保证的鉴证业务。 按照《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求 （2022 年修订）》和《深圳证券交易所上市公司自律监管指引第 2 号-创业板上市公 司规范运作》的要求编制 2024 年度 ...

证券代码：301515 证券简称：港通医疗 公告编号：2025-022 四川港通医疗设备集团股份有限公司 关于预计 2025 年度日常关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 1、日常关联交易概述 3、上一年度关联交易实际发生情况 单位：万元 | 关联交易 | | 关联交 | 实际发 | 2024 年 | | 披露日期及索 | 实际发生额与 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 关联人 | | | 预计金 | | | | | 类别 | | 易内容 | 生金额 | 额 | | 引 | 预计金额差异 | | 接受关联 | 陈永、胡世 | 接受无 | 67,000.00 | 根据实 | - | | | | 方担保 | 红夫妇 | 偿担保 | | 际需求 | | | | | | 四川简阳 | | | | | 2024 年 4 月 24 | | | | | | | | | 日在巨潮资讯 | | | 接受关联 | 港通经济 | 接受无 | 55,500 ...

证券代码：301515 证券简称：港通医疗 公告编号：2025-015 经过各位监事认真审议，本次会议形成如下决议： （一）审议通过《关于公司 2024 年度监事会工作报告的议案》 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《2024 年 度监事会工作报告》。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 四川港通医疗设备集团股份有限公司 第四届监事会第十九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"）第四届监事会第 十九次会议于 2025 年 4 月 17 日在公司会议室以现场表决的方式召开。本次会议 通知于 2025 年 4 月 7 日以通讯方式发出，会议应出席监事 3 人，实际出席监事 3 人。会议由监事会主席施文聪先生召集并主持。本次会议的召集、召开符合《公 司法》和《公司章程》的有关规定，会议合法有效。 一、监事会会议审议情况 该议案尚需提请公司 2024 年年度股东会审议通过，股东会召开时间另行通 知。 （二）审议通过《关于公司 2024 ...

证券代码：301515 证券简称：港通医疗 公告编号：2025-014 四川港通医疗设备集团股份有限公司 第四届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"）第四届董事会第 十九次会议于 2025 年 4 月 17 日在公司会议室以现场及通讯方式召开。本次会议 通知于 2025 年 4 月 7 日以通讯方式发出，会议应出席董事 9 人，实际出席董事 9 人（其中：陈叙先生、魏勇先生、刘煜强先生、赵尘女士以通讯表决方式出席 会议）。会议由董事长陈永先生召集并主持，监事会成员和高级管理人员列席本 次会议。本次会议的召集、召开符合《公司法》和《公司章程》的有关规定，会 议合法有效。 一、董事会会议审议情况 经过各位董事认真审议，本次会议形成如下决议： （一）审议通过《关于公司 2024 年度董事会工作报告的议案》 董事会认为：2024 年度，公司董事会依据有关法律、法规以及规范性文件的 要求，本着对公司和全体股东负责的态度，勤勉尽责履行职责和义务，保障公司 规范运作，促进公司持续健康稳 ...

证券代码：301515 证券简称：港通医疗 公告编号：2025-019 四川港通医疗设备集团股份有限公司 关于 2024 年度利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、四川港通医疗设备集团股份有限公司（以下简称"公司"）拟以实施 2024 年度利润分配方案时股权登记日的总股本（扣除回购专用账户中已回购股份）为基 数，向股权登记日登记在册的全体股东每 10 股派发现金红利人民币 1.20 元（含 税），剩余未分配利润结转以后期间分配。本次不送红股，不进行资本公积转增股 本。 2、本次利润分配方案公布后至实施前，因可转债转股、股份回购、股权激励 行权、再融资新增股份上市等致使公司总股本（扣除回购专用账户中已回购股份） 发生变动的，公司将按照"每股现金分红比例固定不变"的原则对现金分红总额进 行调整。 3、公司不触及《深圳证券交易所创业板股票上市规则》（以下简称《创业板 股票上市规则》）第 9.4 条第（八）项规定的可能被实施其他风险警示情形。 一、审议程序 公司于 2025 年 4 月 17 日召开第四届董事会第十九次会议 ...

Financial Performance - The company's operating revenue has decreased due to market competition and project progress not meeting expectations[4]. - The company's operating revenue for 2024 was ¥754,058,316.42, a decrease of 10.49% compared to ¥842,437,861.81 in 2023[24]. - The net profit attributable to shareholders for 2024 was ¥14,421,866.44, down 82.64% from ¥83,097,173.11 in 2023[24]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥5,008,448.99, a decline of 91.74% from ¥60,627,190.84 in 2023[24]. - The total assets at the end of 2024 were ¥1,946,989,678.97, a decrease of 2.49% from ¥1,996,714,366.68 at the end of 2023[24]. - The net assets attributable to shareholders at the end of 2024 were ¥1,285,002,665.68, down 3.29% from ¥1,328,730,441.04 at the end of 2023[24]. - The basic earnings per share for 2024 were ¥0.1453, an 85.06% decrease from ¥0.9728 in 2023[24]. - The weighted average return on equity for 2024 was 1.10%, down from 9.41% in 2023[24]. - The company reported a significant decline in quarterly performance, with the fourth quarter showing a net profit loss of -¥5,624,438.25[27]. Revenue Breakdown - Revenue from medical gas equipment and systems decreased by 46.50% to 221,936,543.71 CNY, accounting for 29.43% of total revenue[69]. - Revenue from medical clean equipment and systems increased by 32.06% to 493,308,597.63 CNY, representing 65.42% of total revenue[69]. - Operating revenue from maintenance services rose by 16.35% to 13,916,300.05 CNY, making up 1.85% of total revenue[69]. - The Northeast region saw a revenue increase of 102.61%, while the Central region experienced a significant decline of 85.46%[69]. Research and Development - The company plans to continue investing in research and development to enhance product competitiveness and meet market demand[4]. - The R&D team consists of highly qualified professionals across multiple disciplines, ensuring a strong foundation for innovation[51]. - The company has established a comprehensive R&D management mechanism, optimizing resource allocation and enhancing product development capabilities[53]. - Major R&D projects completed include the optimization of medical gas equipment and the development of a new electric surgical table, all aimed at meeting market demands[78][79]. - The company aims to enhance product types and reduce production costs through new product developments, which are expected to drive revenue growth[78][79]. Market Position and Strategy - The company aims to strengthen cost control and shorten the collection period to improve operational capabilities and performance[4]. - The company plans to expand its market presence through partnerships and potential acquisitions to strengthen its competitive position in the medical equipment sector[21]. - The company is actively exploring opportunities in international markets to diversify its revenue streams and reduce dependency on domestic sales[25]. - The company has established strong partnerships with numerous medical institutions, focusing on the sale of medical gas equipment and cleanroom systems, as well as related products[43]. Governance and Compliance - The company has a robust information disclosure system, ensuring timely and accurate reporting to shareholders and regulatory bodies[128]. - The company has maintained a high level of attendance at board meetings, with no directors missing two consecutive meetings[157]. - The company has appointed three independent directors, complying with the requirements set by the China Securities Regulatory Commission[127]. - The company has established a performance evaluation and incentive mechanism for directors, supervisors, and senior management, ensuring transparency and compliance with legal regulations[126]. Cash Flow and Investments - Operating cash inflow for 2024 was CNY 739,860,391.86, a 2.20% increase from CNY 723,934,248.05 in 2023[82]. - Investment cash inflow surged by 831.78% to CNY 384,727,807.37 in 2024 from CNY 41,289,639.28 in 2023[82]. - The total investment during the reporting period was 416 million yuan, reflecting a 100% increase compared to the previous year[92]. - The company has committed to invest a total of 33.5 million in the Smart Medical Equipment Production Base project, with a completion rate of 6% as of July 2023[98]. Employee and Talent Development - The total number of employees at the end of the reporting period is 1,130, with 784 from the parent company and 346 from major subsidiaries[163]. - The company has a strong focus on talent development, providing various training programs to improve employee skills and capabilities[57]. - The company has established a comprehensive annual training plan for 2024, focusing on enhancing employee skills and knowledge through both online and offline training[166]. Risk Management - The company faces risks from intensified market competition, particularly in the medical gas and clean equipment sectors, which may affect its market position[111]. - The company is at risk of bad debts due to increasing accounts receivable from public hospitals, which may be affected by macroeconomic conditions[114]. - To mitigate risks, the company will increase R&D investment and enhance its product pipeline to improve core competitiveness[112]. Environmental and Social Responsibility - The company actively responded to national policies on poverty alleviation and rural revitalization, prioritizing local employment in its projects[181]. - The company has committed to harmonizing economic and social benefits in its operations, contributing to local economic development[181]. - The company strictly adheres to labor laws and regulations, ensuring the protection of employee rights and interests[180].

Revenue and Profitability - Revenue for Q1 2025 was CNY 24,286,732.74, a decrease of 68.09% compared to CNY 76,119,952.75 in the same period last year[5] - Net profit attributable to shareholders was CNY 1,578,952.62, down 85.25% from CNY 10,707,388.40 year-on-year[5] - Basic and diluted earnings per share were CNY 0.0161, down 85.00% from CNY 0.1073 in the same period last year[5] - The net profit for the current period is 1,578,952.62, a significant decrease from 10,707,388.40 in the previous period, representing a decline of approximately 85.2%[20] - The operating profit for the current period is 1,538,872.30, down from 10,618,920.79 in the previous period, indicating a decrease of about 85.5%[20] - The total comprehensive income for the current period is 1,578,952.62, down from 10,707,388.40 in the previous period, reflecting a decrease of about 85.2%[20] Cash Flow and Liquidity - Net cash flow from operating activities was negative CNY 15,090,975.28, a decline of 140.24% compared to CNY 37,498,382.94 in the previous year[5] - Cash flow from operating activities shows a net outflow of -15,090,975.28, compared to a net inflow of 37,498,382.94 in the previous period, reflecting a substantial change in cash flow dynamics[22] - Total cash and cash equivalents at the end of the period stand at 486,663,948.02, down from 694,758,375.54 at the end of the previous period, a decrease of approximately 30%[23] - The company reported cash inflows from investment activities of 81,292,444.44, while cash outflows totaled 195,512,870.38, resulting in a net cash outflow of -114,220,425.94 from investment activities[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,957,273,279.76, an increase of 0.53% from CNY 1,946,989,678.97 at the end of the previous year[5] - The total liabilities at the end of the period are CNY 709,642,530.16, an increase of 7.2% from CNY 661,987,013.29 at the beginning of the period[17] - The accounts receivable decreased to CNY 638,636,200.10, down 9.5% from CNY 705,456,938.63 at the beginning of the period[15] - The inventory increased to CNY 254,737,658.66, up 24.7% from CNY 204,203,626.98 at the beginning of the period[15] Operational Performance - The total operating revenue for the current period is CNY 24,286,732.74, a decrease of 68.1% compared to CNY 76,119,952.75 in the previous period[19] - The total operating costs for the current period amount to CNY 33,730,745.31, down 56.5% from CNY 77,757,539.66 in the previous period[19] - The company experienced a significant reduction in cash inflows from sales of goods and services, which totaled 138,755,526.69, compared to 257,093,414.86 in the previous period, a decline of approximately 46.0%[22] - The company reported a decrease in operating cash inflows, totaling 147,940,993.16, down from 269,434,763.64 in the previous period, indicating a decline of about 45.0%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 8,455[9] - The company has a scheduled release of restricted shares for major shareholders on January 27, 2025, which may impact future stock performance[13] Financing Activities - Short-term borrowings rose by 32.26% year-on-year, primarily due to an increase in working capital loans[10] - The company raised 96,000,000.00 in borrowings during the current period, compared to 75,102,630.93 in the previous period, indicating an increase of approximately 28% in financing activities[23] Research and Development - The company plans to continue focusing on research and development, with R&D expenses amounting to CNY 4,280,463.49 for the current period[19] Inventory Management - Inventory shares increased by 167.17% year-on-year, attributed to the implementation of share buybacks[10] - Prepayments increased by 92.56% year-on-year, mainly due to an increase in procurement prepayments[10] Investment Income - Investment income decreased by 100% year-on-year, as there were no interest earnings from structured deposits in the current period[10]

Core Viewpoint - The company, 港通医疗, is experiencing a decline in stock price and profitability, with a significant drop in net profit despite a modest increase in revenue, indicating potential challenges in the medical device industry [1][2]. Company Overview - 港通医疗 specializes in the research, design, manufacturing, integration, and operation services of medical gas equipment and clean equipment systems [1]. - The company's main products include medical central oxygen systems, medical central suction systems, medical air supply systems, medical gas alarm systems, and medical molecular sieve oxygen systems, among others [1]. - 港通医疗 has obtained 25 medical device registration certificates or filing credentials and was the first in China to pass the National Medical Products Administration's review for medical carbon dioxide excipients [1]. Financial Performance - For the third quarter of 2024, the company reported a revenue of 4.92 billion yuan, representing a year-on-year increase of 13.40% [2]. - The net profit for the same period was 20.0463 million yuan, showing a significant year-on-year decrease of 46.99% [2]. - The company's sales gross margin stood at 20.02% [2]. Market Position - 港通医疗's rolling price-to-earnings (PE) ratio is 27.44, compared to the industry average of 45.94 and the industry median of 29.64, placing it 69th in the industry ranking [1][2]. - The total market capitalization of 港通医疗 is 1.793 billion yuan [2]. - As of the latest report, 62 institutions hold shares in 港通医疗, with a total holding of 1.0387 million shares valued at 0.19 billion yuan [1].

4月14日，港通医疗今日收盘18.12元，上涨1.23%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到27.74倍，总市值18.12亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均45.71倍，行业中值29.99倍，港通医疗排 名第68位。 股东方面，截至2025年3月31日，港通医疗股东户数8455户，较上次减少143户，户均持股市值35.28万 元，户均持股数量2.76万股。 四川港通医疗设备集团股份有限公司主营业务为医用气体装备及系统、医用洁净装备及系统的研发、设 计、制造、集成及运维服务。公司主要产品包括医用中心供氧系统、医用中心吸引系统、医用空气集中 供应系统、医用气体报警系统、医用分子筛制氧系统等Ⅱ类医疗器械及其他成套设备。在医用洁净装备 及系统方面，公司集成净化空调系统、电气系统、智能控制系统及相关设备，主要应用于医院手术部、 ICU、负压隔离病房等区域。公司已取得25项医疗器械注册证或备案凭证。长期以来，公司专注于相关 领域的研发和拓展，2021年3月公司成为国内首家通过国家药监局医用二氧化碳药用辅料关联审评审批 的企业，实现行业突破。 最新一期业绩显示，2024 ...